Silver-nanoparticle-coated biliary stent inhibits bacterial adhesion in bacterial cholangitis in swine

Wei Wen, Li-Mei Ma, Wei He, Xiao-Wei Tang, Yin Zhang, Xiang Wang, Li Liu and Zhi-Ning FanNanjing, China

?

Silver-nanoparticle-coated biliary stent inhibits bacterial adhesion in bacterial cholangitis in swine

Wei Wen, Li-Mei Ma, Wei He, Xiao-Wei Tang, Yin Zhang, Xiang Wang, Li Liu and Zhi-Ning Fan
Nanjing, China

Author Affiliations: Department of Digestive Endoscopy Center, First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China (Wen W, Ma LM, Tang XW, Wang X, Liu L and Fan ZN); Nanjing Medical University, Nanjing 210029, China (Wen W); Department of Gastroenterology, The 81th Hospital of PLA, Nanjing 210002, China (Wen W); Department of Gastroenterology, Changzhou First People’s Hospital, Third Affiliated Hospital of Suzhou University, Changzhou 213003, China (He W and Zhang Y)

The abstract of this study was presented as a poster at the Asia Pacific Digestive Week (APDW 2013), which was held in Shanghai, China on September 21-24, 2013.

? 2016, Hepatobiliary Pancreat Dis Int. All rights reserved.

Published online September 17, 2015.

BACKGROUND: One of the major limitations of biliary stents is the stent occlusion, which is closely related to the overgrowth of bacteria. This study aimed to evaluate the feasibility of a novel silver-nanoparticle-coated polyurethane (Ag/PU) stent in bacterial cholangitis model in swine.

METHODS: Ag/PU was designed by coating silver nanoparticles on polyurethane (PU) stent. Twenty-four healthy pigs with bacterial cholangitis using Ag/PU and PU stents were randomly divided into an Ag/PU stent group (n=12) and a PU stent group (n=12), respectively. The stents were inserted by standard endoscopic retrograde cholangiopancreatography. Laboratory assay was performed for white blood cell (WBC) count, alanine aminotransferase (ALT), interleukin-1β (IL-1β), tumor necrosis factor-α (TNF-α) at baseline time, 8 hours, 1, 2, 3, and 7 days after stent placements. The segment of bile duct containing the stent was examined histologically ex vivo. Implanted biliary stents were examined by a scan electron microscope. The amount of silver release was also measured in vitro.

RESULTS: The number of inflammatory cells and level of ALT, IL-1β and TNF-α were significantly lower in the Ag/PU stent group than in the PU stent group. Hyperplasia of the mucosa was more severe in the PU stent group than in the Ag/PU stent group. In contrast to the biofilm of bacteria on the PU stent, fewer bacteria adhered to the Ag/PU stent.

CONCLUSIONS: PU biliary stents modified with silver nanoparticles are able to alleviate the inflammation of pigs with bacterial cholangitis. Silver-nanoparticle-coated stents are resistant to bacterial adhesion.

(Hepatobiliary Pancreat Dis Int 2016;15:87-92)

KEY WORDS:biliary stent; silver nanoparticles; endoscopic retrograde cholangiopancreatography; bacterial cholangitis

Introduction

It has been more than 30 years since endoscopic biliary stenting was as a standard palliative treatment for obstructive jaundice due to malignant or benign obstruction of bile tracts.[1]Many studies[2-7]have shown that metal biliary stents may offer better palliation and longer patency than plastic stents in patients with malignant biliary obstruction. However, compared to plastic stent, the major disadvantages of metal stents are higher cost and difficult to reposit once deployed. Therefore, the metal stents may be not suitable for benign strictures.[8]

The occlusion of plastic stents remains a major problem in this treatment.[9]It is believed that microbial biofilms resulted from bacterial colonization and sludge deposition are closely associated with biliary stent clogging.[10-12]Antibiotic prophylaxis has been employed to reduce the risk of biliary bacterial colonization.[13]But the antibiotic treatment sometimes leads to allergic reactions (including anaphylaxis) and development of bacterial resistance, and increases costs of medical care. Hence, it is essential to design a new plastic stent to prevent bacterial colonization and biofilm formation.

Silver (Ag) nanoparticles have antimicrobial properties and have been seen as a candidate for antibacterial coating of stents.[14]Coatings using silver salts implanta-tion of metallic silver have been devised.[15, 16]However, they have shown disappointing antibacterial ability because of obliteration or inactivation of the silver coating by blood plasma.

In an attempt to address these shortcomings while taking advantage of the broad antimicrobial spectrum of silver, we designed an Ag nanoparticle-impregnated polymer coating on plastic stents. The present study reports the antimicrobial activity of Ag nanoparticles in pig models and their release in vitro.

Methods

Creation of silver-nanoparticle-coated biliary stent Biliary stents modified with Ag nanoparticles (Ag/PU stents) were prepared by coating Ag/PU composite suspension on polyurethane (PU) biliary stents. The Ag/PU composite suspensions were prepared by in situ reduction method. Firstly, 0.5 mL AgNO3absolute ethanol solution (1 mmol/L) was mixed with 50 mL tetrahydrofuran (THF) solution containing 5 g PU to obtain a PU/ AgNO3solution in THF/ethanol. Then 0.5 mL freshly prepared NaBH4ethanol solution (0.02 mol/L) was added to the above PU/AgNO3solution with vigorous stirring to reduce Ag+to Ag nanoparticles. The bright-brown suspension was obtained after the reaction was completed. This in situ reduction method is able to obtain Ag/PU composite without aggregation of nanoparticles.

Then the Ag/PU composite suspension was cast on PU stent with outer diameter of about 8 mm, wall thickness of 0.3 mm, and length of 40 mm. The PU stent was immersed into the Ag/PU suspension for 10 seconds and slowly pulled out. After the fast evaporation of THF solvent, Ag/PU coating was formed on the PU stent. Because THF can partially dissolve the surface of the PU stent, the Ag/PU coating can be firmly attached to the surface of the PU stent. The control PU biliary stent and Ag/PU biliary stent are shown in Fig. 1. Brown color indicates the presence of Ag nanoparticles about 20 nm in diameter.

Animal preparations

Healthy pigs weighing from 19 to 24 kg (mean 22 kg) were used in the experiments. The experimental procedures were approved by the Animal Use and Care Committee of Nanjing Medical University, China. All the pigs were fasted for two days before the experiments. Anesthesia was induced with 3% pentobarbital by peritoneal injection, followed by an intramuscular injection of 250 mg of ketamine hydrochloride. Cardiac and respiratory parameters were recorded at baseline and 8 hours, 1, 2, 3, and 7 days after the placement of the stent.

After the pigs were anesthetized in the left lateral position, e-duodenoscopy was inserted through the esophagus, stomach into the duodenum. A small plastic tube was passed through the duodenoscope into the ampulla. Then 1.0 mL (15-18×108/mL) of E. coli (model ATCC 25922) solution was injected into the bile duct. The temporary obstruction of the nipple was solved with saline injection (Fig. 2).

Interventions

After the success of modeling (about 8 hours later), either PU stents or Ag/PU stents were intervened in 12 pigs with bacterial cholangitis respectively through an endoscope. The guide wire was sent to the duodenal papilla within the conveyor, then a stent was sent to the bile duct by the wire. Two pigs of each group were sacrificed at days 1 and 7, respectively, to observe bacterial adhesion on the surface of the stent. All the animals were killed by euthanasia.

Serological examination

Fig. 1. Control PU biliary stent (upper) and Ag/PU biliary stent (lower).

Fig. 2. The temporary obstruction of nipple with saline injection.

Blood samples of the thoracic vein of each pig were taken for analysis of white blood cell (WBC) count at 8, 24, 48, 72 hours, and 7 days after modeling. The samples were partly centrifuged for analyzing aspartate aminotrans-ferase (ALT), inflammatory cells, interleukin-1β (IL-1β) and tumor necrosis factor-α (TNF-α) at different time points.

Autopsy and histological examination

At the end of each follow-up, the pigs were euthanized by an intravenous injection of pentobarbital followed by 20 mEq of potassium chloride. All animals underwent a postmortem examination to exclude intraabdominal hemorrhage, seroperitoneum, or peritonitis. The portion of the common bile duct (CBD) containing the stent was dissected out and immediately fixed in a 4% formaldehyde solution. The specimens were embedded in paraffin, sectioned and stained with hematoxylin and eosin. Histological evaluation was performed under a light microscope. The extent of necrosis and the intensity of the inflammation of the CBD wall were assessed by a single pathologist masked to the type of the inserted stent.

Observation of bacterial adhesion on biliary stents

Bacteria and biofilm adhered on PU or Ag/PU stents at days 1 and 7 were evaluated with propidium iodide (PI) staining and observed under a fluorescence inverted microscope (ZEISS Axiovert 200). The morphology of implanted stents at days 1 and 7 was observed with a scan electron microscope (JSM-6300, JEOL, Tokyo, Japan) after fixation and dehydration and gold coating of the bacteria.

Ag+release

To study the kinetics of silver released from the prepared Ag/poly (L-lactic acid) (PLLA) films, the flat or honeycomb-structured Ag/PLLA film was cut into a square shape of 2.0×2.0 cm. After washing with deionized water for ten times and dried, the samples were immersed in 10 mL of the deionized water at 37 ℃ without stirring. At the predetermined time (0, 1, 10, 20, 30, 60 and 90 days), the samples were taken out and the silver ion content of suspending fluids obtained from each time point was analyzed by an atomic absorption spectrometer (AA, Hitachi 180-80).

Statistical analysis

Data were expressed as mean±SD. The data were analyzed using the SPSS v11.5 software (SPSS Inc., Chicago, IL, USA). A P value of <0.05 was considered statistically significant.

Results

Fig. 3. Level of temperature (A), WBC count (B), ALT (C), IL-1β (D), and TNF-α (E) in the PU stent group and Ag/PU stent group in pigs. In the Ag/PU stent group, the number of inflammatory cells and level of ALT, IL-1β and TNF-α in animal models were inhibited to a greater extent than in the PU stent group (*: P<0.05, vs the PU stent group).

The temperature and serological test results are shown in Fig. 3. There were no significant differences in bodytemperature, WBC count, ALT, IL-1β and TNF-α in the two groups before the experiment (P>0.05). The number of inflammatory cells and level of ALT, IL-1β and TNF-α were significantly lower in the Ag/PU stent group than those in the PU stent group (P<0.05).

Seven days after stent implantation, the intumescent bile duct was filled with pus (the yellow mucus flowing out from the CBD) in the PU stent group (Fig. 4A), whereas there was mild inflammation in the CBD of the Ag/PU stent group (Fig. 4B).

Examination of tissue sections of the CBD after the implantation of stents in the PU stent group and Ag/PU stent group under a light microscope is shown in Fig. 5. At the 7-day follow-up, severe hyperplasia of the mucosa was seen in the PU stent group and there was extensive necrotic tissue with increased infiltration of inflammatory cells and neutrophils (Fig. 5A). There was a slight inflammation in the Ag/PU stent group and the number of inflammatory cells and neutrophils was less than that in the PU stent group (Fig. 5B).

Fig. 4. Dissection of pigs on 7 days after stent implantation. A: In the PU stent group, intumescent bile duct was filled with pus (the yellow mucus flowing out from the CBD); B: In the Ag/PU stent group, there was mild inflammation in the CBD.

Fig. 5. Micrographs of tissue sections of the CBD after the implantation of the stents. A: Tissue section of the CBD around the PU stent in the PU stent group at day 7 (arrow represents neutrophils). B: Section of CBD tissue around the Ag/PU stent in the Ag/PU stent group at day 7. In the Ag/PU stent group, the number of inflammatory cells and neutrophils was reduced compared to that in the PU stent group revealing a slight inflammation (HE, original magnification ×400).

The degree of bacterial adhesion on stents in pig models at days 1 and 7 was examined by a fluorescence microscope (Fig. 6) and a scan electron microscope (Fig. 7). Bacterial biofilm was observed on the surface of PU stent at day 1 (Figs. 6A and 7A). And at day 7, PU stent was fully covered with bacteria (Figs. 6B and 7B). In comparison, few bacteria adhere to the Ag/PU stent (Figs. 6C, D and 7C, D).

The amount of Ag+released from Ag/PU stent in deionized water at different periods (0, 1, 10, 20, 30, 60 and 90 days) is illustrated in Fig. 8. This composite coating on PU stent can continuously release Ag+and the Ag+release rate decreases with time. The results suggested that Ag nanoparticles coated on the stent are able to release Ag+with results in bacterial inhibition.

Fig. 6. The fluorescence images of bacterial adhesion on PU stent and Ag/PU stent after implantation in pigs model. PU stent was nearly fully covered with bacteria in B. As for the Ag/PU stent group, the retention of bacteria on Ag/PU stent was greatly inhibited compared with that on PU stent in C and D (PI, original magnification ×400).

Fig. 7. The scan electron microscopy images of bacterial adhesion on PU stent and Ag/PU stent after implantation in pigs model (arrows represent bacterial particle deposition) (original magnification ×5000).

Fig. 8. The amount of Ag+released from Ag/PU stent at different time periods.

Discussion

According to the United States Center for Disease Control and Prevention statistics in 2011, the number of patients died from infection by the built-in medical device ranked No. 5 in the cause of death of hospital patients in the United States. And nosocomial infection in each case leads to an additional cost of 10 000-20 000 US dollors.[17]Therefore, preventing nosocomial catheterrelated infections can greatly reduce the cost of hospitalization and mortality. However, there is currently no artificial device that has the antibacterial features.

With broad spectrum antimicrobial activity and excellent antibacterial efficiency,[18, 19]Ag nanoparticles are considered a good candidate for surface coating in medical devices.[20]Gupta et al[21]reported that silver nanoparticles might be an answer to the drug-resistant microorganisms. The Ag nanoparticles interact with bacteria and confer antimicrobial activity via Ag+.[22]Hence, the antimicrobial activities of Ag-containing materials are often studied in terms of their Ag+release rate. Our in vitro Ag+release test of PU stents coating with Ag nanoparticles revealed that Ag coating is able to achieve a long-term antibacterial effect with the continuous release of Ag+.

Choosing pigs as our experimental animals mainly based on two reasons: 1) the diameter of the bile duct in humans (0.5-10 mm) is similar to that in pigs (0.5-8.0 mm);[23]2) animals are suitable for noninvasive endoscopic procedure.[24]

We chose bacterial infection-related parameters to monitor bacterial cholangitis, and these parameters included body temperature, WBC count, ALT, IL-1β and TNF-α. The baseline of the parameters was not significantly different in the two groups. After stent placement, body temperature, WBC count and IL-1β increased quickly. They began decreasing in 8 hours and continued to decrease slowly afterward. The three parameters in the Ag/PU stent group decreased faster than those in the PU stent group. The changes of ALT and TNF-α were different from those mentioned above. They increased gradually after stent placement. However, compared with the PU stent group, the intervention of Ag/PU stent could slow down the increase rate in the levels of ALT and TNF-α. The recovery of animals in the PU stent group was slower than that in the Ag/PU stent group.

Bacterial biofilm is easily formed on PU stent in short time with accelerated deposition of biliary sludge. According to the images of a scan electron microscope, the biofilm is composed of highly packed E. coli. This complex 3-D structure of biofilm is strongly resist to antibiotics and difficult to be treated. In contrast, only a small amount of bacteria, shaped as a single colony structure, were attached to the surface of Ag/PU stent. On day 7 after implantation, the number of bacteria increased but there was no sign of biofilm formation. The adhesion of bacteria to PLLA surfaces is the first step to biofilm formation. With the accumulation of bacteria on the film surface, adhesion proteins expressed on bacterial surfaces can bind bacteria to the PU surface or with other nearby bacteria. Then, a 3-D community of bacteria and peptidoglycan envelope can form and lead to the development of biofilm.[25]Ag/PU stent reduced bacterial adhesion and inhibited biofilm formation at the initial stage. From the long-term antibacterial efficiency of Ag nanoparticles and the Ag+release results, we predicted that Ag/PU stent effectively prevents biofilm formation and growth in a long period of time.

In conclusion, we developed a novel biliary stent modified with Ag nanoparticles using a facile preparation method. Ag/PU stent is able to efficiently release Ag+for a long period to enable a long-term antibacterial efficiency. The in vivo experiments in pig models confirmed a milder inflammation and greatly reduced bacterial adhesion on Ag/PU stent. This stent is expected to prolong stent patency time and improve the therapeutic effect in future study.

Contributors: FZN proposed the study. WW, MLM and HW performed research and wrote the first draft. TXW, ZY, WX and LL collected and analyzed the data. All authors contributed to the design and interpretation of the study and to further drafts. FZN is the guarantor.

Funding: The study was partially supported by grants from theJiangsu Province Social Development Program (BL2012031), the National Natural Science Foundation of China (81172266), the Natural Science Foundation of Jiangsu Province (BK2011859) and Jiangsu Innovation of Medical Team and Leading Talents Cultivation (LJ201127).

Ethical approval: This study was approved by the Animal Use and Care Committee of Nanjing Medical University, China.

Competing interest: No benefits in any form have been received or will be received from a commercial party related directly or indirectly to the subject of this article.

References

1 Soehendra N, Reynders-Frederix V. Palliative biliary duct drainage. A new method for endoscopic introduction of a new drain. Dtsch Med Wochenschr 1979;104:206-207.

2 Weber A, Mittermeyer T, Wagenpfeil S, Schmid RM, Prinz C. Self-expanding metal stents versus polyethylene stents for palliative treatment in patients with advanced pancreatic cancer. Pancreas 2009;38:e7-e12.

兩組一般臨床資料比較顯示，兩組在性別上比較，差異無統(tǒng)計(jì)學(xué)意義（P＞0.05）。冠心病組中吸煙、高血壓、高血脂、糖尿病患者數(shù)量明顯高于對(duì)照組，組間比較，差異有統(tǒng)計(jì)學(xué)意義（P＜0.05）。表明以上因子均為冠心病的危險(xiǎn)因素。見表1。

3 Yoon WJ, Ryu JK, Yang KY, Paik WH, Lee JK, Woo SM, et al. A comparison of metal and plastic stents for the relief of jaundice in unresectable malignant biliary obstruction in Korea: an emphasis on cost-effectiveness in a country with a low ERCP cost. Gastrointest Endosc 2009;70:284-289.

4 Conio M, Blanchi S, Filiberti R, De Ceglie A. Self-expanding plastic stent to palliate symptomatic tissue in/overgrowth after self-expanding metal stent placement for esophageal cancer. Dis Esophagus 2010;23:590-596.

5 Decker C, Christein JD, Phadnis MA, Wilcox CM, Varadarajulu S. Biliary metal stents are superior to plastic stents for preoperative biliary decompression in pancreatic cancer. Surg Endosc 2011;25:2364-2367.

6 Moses PL, Alnaamani KM, Barkun AN, Gordon SR, Mitty RD, Branch MS, et al. Randomized trial in malignant biliary obstruction: plastic vs partially covered metal stents. World J Gastroenterol 2013;19:8638-8646.

7 Bhalala M, Rude K, Wang A, Sauer B, White GE, Kahaleh M, et al. Analysis of complications after EUS-FNA in patients with obstructive jaundice and drained with plastic biliary stents or self-expandable metal stents (SEMS): do complications differ between the type of stent? J Interv Gastroenterol 2013;3:128-132.

8 Moss AC, Morris E, Leyden J, MacMathuna P. Do the benefits of metal stents justify the costs? A systematic review and metaanalysis of trials comparing endoscopic stents for malignant biliary obstruction. Eur J Gastroenterol Hepatol 2007;19:1119-1124.

9 Donelli G, Guaglianone E, Di Rosa R, Fiocca F, Basoli A. Plastic biliary stent occlusion: factors involved and possible preventive approaches. Clin Med Res 2007;5:53-60.

10 Guaglianone E, Cardines R, Vuotto C, Di Rosa R, Babini V, Mastrantonio P, et al. Microbial biofilms associated with biliary stent clogging. FEMS Immunol Med Microbiol 2010;59:410-420.

11 Hoffman BJ, Cunningham JT, Marsh WH, O’Brien JJ, Watson J. An in vitro comparison of biofilm formation on various biliary stent materials. Gastrointest Endosc 1994;40:581-583.

12 Libby ED, Leung JW. Prevention of biliary stent clogging: a clinical review. Am J Gastroenterol 1996;91:1301-1308.

13 Demirba? AE, Karademir A, Parlak E, Sen S, Karahan M, Kayaalp C, et al. Multidrug resistance of isolated microorganisms in occluded bile duct stents. Turk J Gastroenterol 2007;18:33-40.

14 Shahverdi AR, Fakhimi A, Shahverdi HR, Minaian S. Synthesis and effect of silver nanoparticles on the antibacterial activity of different antibiotics against Staphylococcus aureus and Escherichia coli. Nanomedicine 2007;3:168-171.

15 Lai KK, Fontecchio SA. Use of silver-hydrogel urinary catheters on the incidence of catheter-associated urinary tract infections in hospitalized patients. Am J Infect Control 2002;30:221-225.

16 Crabtree JH, Burchette RJ, Siddiqi RA, Huen IT, Hadnott LL, Fishman A. The efficacy of silver-ion implanted catheters in reducing peritoneal dialysis-related infections. Perit Dial Int 2003;23:368-374.

17 Wenzel RP, Edmond MB. The impact of hospital-acquired bloodstream infections. Emerg Infect Dis 2001;7:174-177.

18 Choi JH, An MY, Lee BM, Kim DK, Jung CH, Hwang IT, et al. Micropatterning of poly(vinyl pyrrolidone)/silver nanoparticle thin films by ion irradiation. J Nanosci Nanotechnol 2009;9:7090-7093.

19 Lok CN, Ho CM, Chen R, He QY, Yu WY, Sun H, et al. Proteomic analysis of the mode of antibacterial action of silver nanoparticles. J Proteome Res 2006;5:916-924.

20 Kim JS, Kuk E, Yu KN, Kim JH, Park SJ, Lee HJ, et al. Antimicrobial effects of silver nanoparticles. Nanomedicine 2007;3:95-101.

21 Gupta A, Bonde SR, Gaikwad S, Ingle A, Gade AK, Rai M. Lawsonia inermis-mediated synthesis of silver nanoparticles: activity against human pathogenic fungi and bacteria with special reference to formulation of an antimicrobial nanogel. IET Nanobiotechnol 2014;8:172-178.

22 Lok CN, Ho CM, Chen R, He QY, Yu WY, Sun H, et al. Silver nanoparticles: partial oxidation and antibacterial activities. J Biol Inorg Chem 2007;12:527-534.

23 Laukkarinen JM, Sand JA, Chow P, Juuti H, Kellom?ki M, K?rkk?inen P, et al. A novel biodegradable biliary stent in the normal duct hepaticojejunal anastomosis: an 18-month follow-up in a large animal model. J Gastrointest Surg 2007;11: 750-757.

24 Itoi T, Kasuya K, Abe Y, Isayama H. Endoscopic placement of a new short-term biodegradable pancreatic and biliary stent in an animal model: a preliminary feasibility study (with videos). J Hepatobiliary Pancreat Sci 2011;18:463-467.

25 Bos R, van der Mei HC, Busscher HJ. Physico-chemistry of initial microbial adhesive interactions--its mechanisms and methods for study. FEMS Microbiol Rev 1999;23:179-230.

Received September 1, 2014

Accepted after revision June 8, 2015

Original Article / Pancreas

doi:10.1016/S1499-3872(15)60410-6

Corresponding Author:Zhi-Ning Fan, MD, PhD, Department of Digestive Endoscopy Center, First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China (Tel/Fax: +86-25-58509931; Email: fanzhining@njmu.edu.cn)